# Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Study · id `cardio:ct-nct06145360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06145360](<https://clinicaltrials.gov/study/NCT06145360>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06145360

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT06145360. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT06145360, source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)
- Started: 2023-12-01 (actual) (ClinicalTrials.gov record NCT06145360, source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)
- Primary completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06145360, source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)
- Completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06145360, source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT06145360, source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06145360-2024-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
- Condition: Glucose Metabolism Disorders
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypoglycemic Agents
- Condition: Empagliflozin
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Insulin+Metformin+DPP4 inhibitor (DPP4I)
- Lead sponsor: SINA Health Education and Welfare Trust
- Lead sponsor class: OTHER
- Collaborator: Horizon Pharmaceutical Pvt Ltd
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 0b73ee0a6d7bc840693eef31eddb6b74fb111a06e06c1b62f381fe00c41176b5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
